SC
BCRX icon

Syon Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Syon Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,105
Closed -$90.8K – 736
2025
Q1 		$90.8K Sell
12,105
-1,044
-8% -$8.42K 0.01% 578
2024
Q4 		$98.9K Buy
+13,149
New +$99.8K 0.01% 548

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Syon Capital's BCRX Position: Q2 2025 in Review

Syon Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 12,105 shares — an estimated $90.8K sold.

Syon Capital first reported a position in BCRX in Q4 2024 and held it in 2 quarters. The position peaked at $98.9K in Q4 2024. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

  • Syon Capital reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Syon Capital sold 12,105 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $90.8K.
  • Syon Capital first reported a position in BioCryst Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Syon Capital's BioCryst Pharmaceuticals position peaked at $98.9K in Q4 2024.
  • 294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Syon Capital's 13F filing for Q2 2025, filed 14 Aug 2025.